arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

GRAIL, Inc.

GRAL Health Care Medical Specialities
$80.84
▲ +0.6% Today
as of Sep 4, 16:49 ET
Last 30 days +24.71% Jul 28 → Sep 04
$61.87 $67.42 $72.97 $78.52 $84.07 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$79.92
High
$80.44
Low
$78.50
Volume
$433,412
Avg Vol
$954,403
Mkt Cap
$3.5B
P/E (TTM)
—
Beta
—
52w High
$118.84
52w Low
$35.39
Div Yield
—
Shares Out
$45M

Recent Press Releases & News last 60 days · 17 items

Sep 4 · 12:10 Motley Fool
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test
Sep 3 · 20:02 PR PR Newswire
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 31 · 20:01 PR PR Newswire
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
▸ Show all 17 press releases & news Free account →

Overview

52-week range
$35
$119
54% of range
Avg surprise (last 3)
+15.2%
Avg reaction (last 2)
+8.5%
50% positive
Latest IV / EM
75%
EM ±11.8% · $80 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-51.06$-37.55$-24.03$-10.52$3.00 Actual $-6.22Actual $-28.71Actual $-7.05Actual $-51.06Actual $-3.94Actual $-3.10Est $-4.03Actual $-3.18Est $-3.14Actual $-2.46Actual $-2.29Est $3.00Actual $-2.56 JunOctMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-126M$-83M$-39M$4M$47M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-2.56 — — — — financials
Tue May 5, 2026Mar/2026 $-2.29 $3.00 +23.7% +26.1% -2.3% earnings
Tue Sep 30, 2025Sep 2025 $-2.46 — — — — financials
Tue Aug 12, 2025Jun/2025 $-3.18 $-3.14 -1.3% — — earnings
Tue May 13, 2025Mar/2025 $-3.10 $-4.03 +23.1% — +19.2% earnings
Mon Sep 30, 2024Sep 2024 $-3.94 — — — — financials
Sun Jun 30, 2024Jun 2024 $-51.06 — — — — financials
Sun Mar 31, 2024Mar 2024 $-7.05 — — — — financials
Sun Oct 1, 2023Oct 2023 $-28.71 — — — — financials
Fri Jun 30, 2023Jun 2023 $-6.22 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$45M$41M—$36M$36M$32M—$29M
Cost of revenue————————
Gross profit————————
Operating income$-174M$-136M—$-125M$-159M$-154M—$-184M
Net income$-110M$-93M—$-89M$-114M$-106M—$-126M
EPS (diluted)$-2.56$-2.29—$-2.46$-3.18$-3.10—$-3.94

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$56M$69M$250M$127M$127M$134M$214M$854M
Inventory————————
Total current assets$915M$877M$954M$589M$652M$728M$820M$910M
Total assets$2.84B$2.80B$2.92B$2.60B$2.70B$2.85B$2.98B$3.12B
Long-term debt————————
Total liabilities$301M$303M$344M$361M$388M$434M$480M$530M
Total equity$2.54B$2.50B$2.58B$2.24B$2.31B$2.41B$2.50B$2.59B

Implied volatility — last 90 days

67%83%100%116%132% Jun 07 — IV 102% · EM ±14.2%Jun 08 — IV 92% · EM ±12.2%Jun 09 — IV 94% · EM ±11.8%Jun 10 — IV 100% · EM ±11.8%Jun 11 — IV 90% · EM ±9.9%Jun 12 — IV 89% · EM ±9.1%Jun 15 — IV 103% · EM ±7.4%Jun 16 — IV 107% · EM ±6.3%Jun 17 — IV 133% · EM ±5.6%Jun 19 — IV 87% · EM ±19.1%Jun 22 — IV 83% · EM ±17.2%Jun 23 — IV 84% · EM ±17.1%Jun 24 — IV 96% · EM ±19.3%Jun 25 — IV 81% · EM ±15.9%Jun 26 — IV 76% · EM ±14.6%Jun 29 — IV 82% · EM ±14.5%Jun 30 — IV 80% · EM ±13.7%Jul 01 — IV 80% · EM ±13.4%Jul 02 — IV 70% · EM ±11.4%Jul 03 — IV 73% · EM ±11.4%Jul 06 — IV 91% · EM ±12.6%Jul 07 — IV 86% · EM ±11.4%Jul 08 — IV 86% · EM ±10.7%Jul 09 — IV 72% · EM ±8.5%Jul 10 — IV 76% · EM ±8.4%Jul 13 — IV 108% · EM ±9.0%Jul 14 — IV 121% · EM ±8.8%Jul 15 — IV 89% · EM ±5.3%Jul 16 — IV 127% · EM ±5.3%Jul 20 — IV 87% · EM ±20.5%Jul 21 — IV 85% · EM ±19.9%Jul 22 — IV 84% · EM ±19.3%Jul 23 — IV 79% · EM ±17.8%Jul 24 — IV 93% · EM ±20.6%Jul 27 — IV 79% · EM ±16.4%Jul 28 — IV 93% · EM ±19.1%Jul 29 — IV 83% · EM ±16.7%Jul 30 — IV 98% · EM ±19.2%Jul 31 — IV 100% · EM ±19.1%Aug 03 — IV 103% · EM ±18.3%Aug 04 — IV 104% · EM ±17.9%Aug 05 — IV 103% · EM ±17.2%Aug 06 — IV 67% · EM ±10.9%Aug 07 — IV 74% · EM ±11.6%Aug 10 — IV 85% · EM ±11.8%Aug 11 — IV 70% · EM ±9.2%Aug 12 — IV 75% · EM ±9.4%Aug 13 — IV 72% · EM ±8.5%Aug 14 — IV 71% · EM ±7.8%Aug 17 — IV 81% · EM ±6.8%Aug 18 — IV 87% · EM ±6.3%Aug 19 — IV 131% · EM ±7.8%Aug 20 — IV 120% · EM ±5.0%Aug 24 — IV 75% · EM ±15.7%Aug 25 — IV 76% · EM ±15.6%Aug 26 — IV 82% · EM ±16.5%Aug 27 — IV 81% · EM ±15.8%Aug 28 — IV 83% · EM ±15.8%Aug 31 — IV 85% · EM ±15.0%Sep 01 — IV 76% · EM ±13.0%Sep 02 — IV 84% · EM ±14.0%Sep 03 — IV 73% · EM ±11.8%Sep 04 — IV 75% · EM ±11.8%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in